Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $3.28 USD
Change Today -0.03 / -0.91%
Volume 847.9K
CRIS On Other Exchanges
As of 5:20 PM 07/1/15 All times are local (Market data is delayed by at least 15 minutes).

curis inc (CRIS) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/2/15 - $3.65
52 Week Low
12/18/14 - $1.09
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CURIS INC (CRIS)

curis inc (CRIS) Related Businessweek News

No Related Businessweek News Found

curis inc (CRIS) Details

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers. The company develops CUDC-907, an oral small molecule inhibitor of histone deacetylase and phosphatidylinositol-3-kinase enzymes, which is in Phase I clinical trials for advanced lymphomas and multiple myeloma; and HER 2-/ ER+ or PR+ breast cancer, and NUT midline carcinoma. It also develops CUDC-427 that is in Phase I clinical trials for advanced solid tumor and lymphomas; programmed death ligand-1 antagonist, which is in preclinical stage for the treatment of cancers; small molecule Interleukin-1 receptor-associated kinase 4 inhibitor that is in preclinical stage for the treatment of hematological cancers; and CUDC-305 drug candidate, which is in trials in patients with systemic mastocytosis and glioblastoma multiforme for the treatment of cancers. In addition, the company offers Erivedge, an orally-administered small molecule hedgehog pathway inhibitor for advanced basal cell carcinoma (BCC). Its Erivedge is also in Phase II clinical trials for preceding excision and/or multiple BCC, and idiopathic pulmonary fibrosis. The company has collaboration agreement with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and collaboration and license agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.

35 Employees
Last Reported Date: 02/24/15
Founded in 2000

curis inc (CRIS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $464.2K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $399.7K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $409.7K
Vice Chairman and Strategic Advisor
Total Annual Compensation: $226.3K
Vice President of Technology Management & Int...
Total Annual Compensation: $230.0K
Compensation as of Fiscal Year 2014.

curis inc (CRIS) Key Developments

Curis, Inc.(NasdaqGM:CRIS) added to Russell 2000 Index

Curis, Inc. will be added to Russell 2000 Index

Curis, Inc.(NasdaqGM:CRIS) added to Russell 3000 Index

Curis, Inc. will be added to the Russell 3000 Index.

Curis, Inc. Presents Phase 1 Study of CUDC-907 at ASCO Annual Meeting

Curis, Inc. announced that clinical data from two programs will be presented at the Annual Meeting of American Society of Clinical Oncology (ASCO), being held from May 29 - June 2, 2015 in Chicago, IL. Curis' study investigators will present data from the Phase 1 study of CUDC-907, Curis' proprietary oral, dual histone deacetylase (HDAC) and phosphoinositide 3-kinase (PI3K) inhibitor that is being studied in the ongoing expansion stage of a Phase 1 trial, with a focus on patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The U.S. FDA recently granted Orphan Drug Designation to CUDC-907 for the treatment of DLBCL. Curis is also conducting a separate Phase 1 trial to investigate CUDC-907 in patients with advanced solid tumors, including those with advanced hormone receptor positive breast cancer or with NUT midline carcinoma. In addition, data will be presented from clinical studies of Erivedge, a first-in-class hedgehog pathway inhibitor approved for the treatment of advanced basal cell carcinoma (BCC). Roche and Genentech, a member of the Roche Group, develop and commercialize Erivedge under a collaboration agreement with Curis.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CRIS:US $3.28 USD -0.03

CRIS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ArQule Inc $1.56 USD -0.04
CTI BioPharma Corp $2.02 USD +0.07
Cytokinetics Inc $6.52 USD -0.20
Exelixis Inc $3.49 USD -0.27
Navidea Biopharmaceuticals Inc $1.62 USD +0.01
View Industry Companies

Industry Analysis


Industry Average

Valuation CRIS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 35.0x
Price/Book 4.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 29.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CURIS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at